Eisai Co., Ltd. and Biogen Inc., announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in th...
Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, announced that t...
Lexicon Pharmaceuticals, Inc. announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achiev...
SciSparc Ltd.(“Company” or “SciSparc”), announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Lakefront Biotherapeutics NV announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the ...
Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” announced that Opamtistomig (LBL-024), the Company&rsquo...
Ipsen announced it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navt...
Johnson & Johnson announced that the European Commission (EC) has approved an indication extension for TECVAYLI®(teclistamab) in combination with...
Milestone® Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medi...
Orum Therapeutics(“Orum” or the “Company”), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), ...
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by po...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced the opening of STAIR-HIV (Small Trial of Alendronate Impac...
Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced the continued advancement of its AI ecosystem – ...
RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 m...
© 2026 Biopharma Boardroom. All Rights Reserved.
